NASDAQ:PRQR

Proqr Therapeutics N.v Stock Insider Trading

Healthcare > Biotechnology

Buy PRQR

*Your capital is at risk

$1.70

-0.0300 (-1.73%)

At Close: Jul 13, 2026

ProQR Therapeutics N.V Stock Insider Power

Based on the 96 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 10.85M and sold 0 PRQR shares in the last 96 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 96 transactions)	100.00
● Buy	10.85M shares
● Sell	0 shares
100% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 07, 2026 Buy	Ordinary Shares P-Purchase	De Boer Daniel Anton Chief Executive Officer	CEO / President	150 000 Value: $238.5K
Jun 26, 2026 Buy	Ordinary Shares P-Purchase	Filius Bart Director	Director	150 000 Value: $231.0K
Jun 02, 2026 Buy	Share Option (Right to Buy) A-Award	Hinsch Gylvin Lykke Director	Director	14 595 Value: $20.7K
Jun 02, 2026 Buy	Common Stock J-Other	Hinsch Gylvin Lykke	Director	0 Value: $0
Mar 18, 2026 Buy	Share Option (Right to Buy)	Valerio Domenico Director	Director	27 500 Value: $90.8K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Valerio Domenico Director	Director	14 918 Value: $235.4K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Valerio Domenico Director	Director	24 615 Value: $243.9K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Valerio Domenico Director	Director	23 239 Value: $97.6K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Valerio Domenico Director	Director	23 931 Value: $191.7K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Valerio Domenico Director	Director	22 608 Value: $77.1K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Valerio Domenico Director	Director	23 489 Value: $46.5K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Valerio Domenico Director	Director	22 128 Value: $58.6K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Valerio Domenico Director	Director	25 192 Value: $50.9K
Mar 18, 2026 Buy	Ordinary Shares	Platenburg Gerardus Johannes Chief Scientific Officer	Officer	0 Value: $0
Mar 18, 2026 Buy	Share Option (Right to Buy)	Platenburg Gerardus Johannes Chief Scientific Officer	Officer	61 453 Value: $301.1K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Platenburg Gerardus Johannes Chief Scientific Officer	Officer	71 409 Value: $235.6K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Platenburg Gerardus Johannes Chief Scientific Officer	Officer	17 878 Value: $282.1K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Platenburg Gerardus Johannes Chief Scientific Officer	Officer	141 369 Value: $1.40M
Mar 18, 2026 Buy	Share Option (Right to Buy)	Platenburg Gerardus Johannes Chief Scientific Officer	Officer	79 033 Value: $331.9K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Platenburg Gerardus Johannes Chief Scientific Officer	Officer	77 353 Value: $78.9K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Platenburg Gerardus Johannes Chief Scientific Officer	Officer	172 603 Value: $115.6K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Platenburg Gerardus Johannes Chief Scientific Officer	Officer	152 000 Value: $518.3K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Platenburg Gerardus Johannes Chief Scientific Officer	Officer	164 715 Value: $326.1K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Platenburg Gerardus Johannes Chief Scientific Officer	Officer	159 358 Value: $422.3K
Mar 18, 2026 Buy	Share Option (Right to Buy)	Platenburg Gerardus Johannes Chief Scientific Officer	Officer	186 139 Value: $376.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PROQR THERAPEUTICS N.V.

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in...

Read Full Profile Here